ilmscore | Prediction Details
"One Challenge they will face is that they are losing exclusivity with the Huma drug in 2023 which is next year so that means there is going to be more compet ition for that particular space in the drug field"
By Humphrey Yang | September 21, 2022 | Pending
From video
7 Dividend Stocks That Pay Me $500+ Per Month 00:05:20 - 00:05:32
Interpreted Prediction
AbbVie is predicted to face increased competition for its Humira drug due to loss of exclusivity in 2023.

Prediction Details

Ticker
ABBV
Initial Price
140.31 USD

Comments

0 comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.